Douwe Postmus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6921357/publications.pdf

Version: 2024-02-01

201674 243625 2,102 66 27 44 citations h-index g-index papers 67 67 67 3396 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1973-1981.	2.8	159
2	Hit-And-Run enables efficient weight generation for simulation-based multiple criteria decision analysis. European Journal of Operational Research, 2013, 224, 552-559.	5.7	122
3	Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2378-2388.	2.8	108
4	A stochastic multicriteria model for evidenceâ€based decision making in drug benefitâ€risk analysis. Statistics in Medicine, 2011, 30, 1419-1428.	1.6	88
5	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation, 2021, 143, 438-448.	1.6	85
6	Survival and Quality of Life After Stereotactic or 3D-Conformal Radiotherapy for Inoperable Early-Stage Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e291-e297.	0.8	76
7	Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators. Clinical Pharmacology and Therapeutics, 2016, 99, 548-554.	4.7	70
8	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <scp>PROTECT</scp> study. European Journal of Heart Failure, 2016, 18, 830-839.	7.1	70
9	Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia, 2012, 55, 1963-1970.	6.3	66
10	Multicriteria benefit–risk assessment using network meta-analysis. Journal of Clinical Epidemiology, 2012, 65, 394-403.	5.0	63
11	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 59-67.	3.9	60
12	Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. Oncologist, 2018, 23, 44-51.	3.7	53
13	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International, 2022, 101, 174-184.	5.2	53
14	Understanding Patients' Preferences: A Systematic Review of Psychological Instruments Used in Patients' Preference and Decision Studies. Value in Health, 2019, 22, 491-501.	0.3	51
15	Plasma Procalcitonin Is Associated with Obesity, Insulin Resistance, and the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E26-E31.	3.6	49
16	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without HeartÂFailure. JACC: Heart Failure, 2021, 9, 807-820.	4.1	49
17	Long-Term Compliance With Nonpharmacologic Treatment of Patients With Heart Failure. American Journal of Cardiology, 2012, 110, 392-397.	1.6	48
18	Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. European Journal of Heart Failure, 2018, 20, 89-96.	7.1	48

#	Article	IF	Citations
19	Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment. Medical Decision Making, 2015, 35, 859-871.	2.4	44
20	Mediterranean style diet is associated with low risk of new-onset diabetes after renal transplantation. BMJ Open Diabetes Research and Care, 2017, 5, e000283.	2.8	43
21	Peroxiredoxin 4, A Novel Circulating Biomarker for Oxidative Stress and the Risk of Incident Cardiovascular Disease and All ause Mortality. Journal of the American Heart Association, 2012, 1, e002956.	3.7	42
22	The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. European Journal of Heart Failure, 2012, 14, 168-175.	7.1	42
23	The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure. JACC: Heart Failure, 2013, 1, 164-169.	4.1	40
24	Plasma biomarkers to predict or rule out early postâ€discharge events after hospitalization for acute heart failure. European Journal of Heart Failure, 2017, 19, 728-738.	7.1	34
25	A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. American Heart Journal, 2011, 162, 1096-1104.	2.7	33
26	THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS. International Journal of Technology Assessment in Health Care, 2016, 32, 46-53.	0.5	32
27	Notes on â€~Hit-And-Run enables efficient weight generation for simulation-based multiple criteria decision analysis'. European Journal of Operational Research, 2014, 239, 865-867.	5.7	31
28	Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia, 2011, 54, 2463-2465.	6.3	25
29	Quantitative release planning in extreme programming. Information and Software Technology, 2011, 53, 1227-1235.	4.4	24
30	Probability Elicitation to Inform Early Health Economic Evaluations of New Medical Technologies: A Case Study in Heart Failure Disease Management. Value in Health, 2013, 16, 529-535.	0.3	24
31	Prognostic Value of Serial Galectinâ€3 Measurements in Patients With Acute Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	24
32	Former Smoking Is a Risk Factor for Chronic Kidney Disease After Lung Transplantation. American Journal of Transplantation, 2011, 11, 2490-2498.	4.7	23
33	Hepatorenal dysfunction identifies highâ€risk patients with acute heart failure: insights from the RELAXâ€AHF trial. ESC Heart Failure, 2019, 6, 1188-1198.	3.1	22
34	Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives. Biometrical Journal, 2015, 57, 556-570.	1.0	21
35	A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. Diabetologia, 2010, 53, $2562-2568$.	6.3	19
36	A method for the early health technology assessment of novel biomarker measurement in primary prevention programs. Statistics in Medicine, 2012, 31, 2733-2744.	1.6	18

#	Article	IF	CITATIONS
37	A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions. European Journal of Health Economics, 2014, 15, 709-716.	2.8	18
38	Hemoglobin levels and new-onset heart failure in the community. American Heart Journal, 2015, 169, 94-101.e2.	2.7	18
39	An economic model to compare the profitability of pay-per-use and fixed-fee licensing. Information and Software Technology, 2009, 51, 581-588.	4.4	17
40	Incidence of impaired renal function after lung transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 238-243.	0.6	17
41	Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. Annals of the American Thoracic Society, 2022, 19, 227-237.	3.2	16
42	Continuous-Time Semi-Markov Models in Health Economic Decision Making. Medical Decision Making, 2016, 36, 59-71.	2.4	15
43	Diagnostic reliability of low dose multidetector CT and cone beam CT in maxillofacial trauma—an experimental blinded and randomized study. Dentomaxillofacial Radiology, 2018, 47, 20170423.	2.7	14
44	Assessment of Cotinine Reveals a Dose-Dependent Effect of Smoking Exposure on Long-term Outcomes After Renal Transplantation. Transplantation, 2015, 99, 1926-1932.	1.0	11
45	Derivation and validation of a prognostic model for predicting in-hospital mortality in patients admitted with COVID-19 in Wuhan, China: the PLANS (platelet lymphocyte age neutrophil sex) model. BMC Infectious Diseases, 2020, 20, 959.	2.9	11
46	Determinants of quality of life in acute heart failure patients with and without comorbidities: a prospective, observational study. European Journal of Cardiovascular Nursing, 2022, 21, 205-212.	0.9	10
47	The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications. Cost Effectiveness and Resource Allocation, 2018, 16, 23.	1.5	9
48	Aligning the economic modeling of software reuse with reuse practices. Information and Software Technology, 2008, 50, 753-762.	4.4	8
49	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. Cardiovascular Drugs and Therapy, 2017, 31, 281-293.	2.6	8
50	Using Multicriteria Decision Analysis to Support Research Priority Setting in Biomedical Translational Research Projects. BioMed Research International, 2015, 2015, 1-9.	1.9	7
51	From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs. Medical Decision Making, 2019, 39, 879-885.	2.4	7
52	Long-term outcomes of atrioventricular septal defect and single ventricle: A multicenter study. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 1166-1175.	0.8	7
53	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 890-903.	4.1	7
54	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure â€" Post-hoc analysis of the PROTECT trial. International Journal of Cardiology, 2016, 223, 967-975.	1.7	6

#	Article	IF	CITATIONS
55	Urinary sulfate excretion and risk of late graft failure in renal transplant recipients – a prospective cohort study. Transplant International, 2020, 33, 752-761.	1.6	6
56	Using joint modelling to assess the association between a time-varying biomarker and a survival outcome: an illustrative example in respiratory medicine. European Respiratory Journal, 2021, 57, 2003206.	6.7	6
57	Microsimulation for Clinical Decision-Making in Individual Patients With Established Coronary Artery Disease. Circulation Journal, 2013, 77, 717-724.	1.6	5
58	Design of stepwise screening for prediabetes and type 2 diabetes based on costs and cases detected. Journal of Clinical Epidemiology, 2015, 68, 1010-1018.	5.0	5
59	A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts. BMC Medicine, 2021, 19, 21.	5.5	5
60	Should non-cardiovascular mortality be considered in the SCORE model? Findings from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort. European Journal of Epidemiology, 2015, 30, 47-56.	5.7	3
61	Product and Release Planning Practices for Extreme Programming. Lecture Notes in Business Information Processing, 2010, , 238-243.	1.0	3
62	Prediction of Poor Outcome for Cutaneous Squamous Cell Carcinoma of the Head and Neck Comparing Classification Systems: A Competing Risk Analysis. Journal of Investigative Dermatology, 2022, 142, 2532-2534.e4.	0.7	2
63	Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration. European Journal of Health Economics, 2019, 20, 475-482.	2.8	1
64	Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study. Frontiers in Pharmacology, 2020, 11, 617409.	3. 5	1
65	Towards Model-driven Evolvability of Enterprise Information Systems. , 2006, , .		O
66	Tools and Techniques $\hat{a}\in$ Statistical. Estimating cumulative incidences in the presence of right-censoring and competing risks: an introduction with illustrations from the COACH study. EuroIntervention, 2016, 11, e1322-e1324.	3.2	0